Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond. (Q38020145)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22714999%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22714999%20AND%20SRC:MED&resulttype=core&format=json

acute promyelocytic leukemia

5 February 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22714999%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Guangbiao Zhou

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22714999%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Sai-Juan Chen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22714999%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

19 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22714999%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22714999%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22714999%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22714999%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

671-675

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22714999%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

cites work

Cancer statistics, 2009

1 reference

Global cancer statistics, 2002

21 January 2018

1 reference

21 January 2018

Global cancer statistics

1 reference

Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group

21 January 2018

1 reference

Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

21 January 2018

1 reference

From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia

21 January 2018

1 reference

Acute promyelocytic leukemia: from highly fatal to highly curable

21 January 2018

1 reference

Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.

21 January 2018

1 reference

From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.

21 January 2018

1 reference

The history of acute promyelocytic leukaemia.

21 January 2018

1 reference

Retinoic acid and arsenic for treating acute promyelocytic leukemia

21 January 2018

1 reference

Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia

21 January 2018

1 reference

PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia

21 January 2018

1 reference

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus

21 January 2018

1 reference

Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML

21 January 2018

1 reference

Acute Promyelocytc Leukemia

21 January 2018

1 reference

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia

21 January 2018

1 reference

Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid

21 January 2018

1 reference

Control of Normal Differentiation of Myeloid Leukemic Cells to Macrophages and Granulocytes

21 January 2018

1 reference

In vitro induction of granulocyte differentiation in hematopoietic cells from leukemic and non-leukemic patients

21 January 2018

1 reference

The differentiation of myeloid leukaemia cells: new possibilities for therapy

21 January 2018

1 reference

Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis

21 January 2018

1 reference

Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies

21 January 2018

1 reference

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

21 January 2018

1 reference

Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data

21 January 2018

1 reference

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia

21 January 2018

1 reference

Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.

21 January 2018

1 reference

Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins

21 January 2018

1 reference

Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation

21 January 2018

1 reference

Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus

21 January 2018

1 reference

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

21 January 2018

1 reference

PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.

21 January 2018

1 reference

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

21 January 2018

1 reference

Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo

21 January 2018

1 reference

Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas

21 January 2018

1 reference

Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector

21 January 2018

1 reference

A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis

21 January 2018

1 reference

Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts

21 January 2018

1 reference

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.

21 January 2018

1 reference

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice

21 January 2018

1 reference

Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo

21 January 2018

1 reference

Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein.

21 January 2018

1 reference

Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells.

21 January 2018

1 reference

Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells

21 January 2018

1 reference

Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein

21 January 2018

1 reference

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

21 January 2018

1 reference

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia

21 January 2018

1 reference

PML targeting eradicates quiescent leukaemia-initiating cells

21 January 2018

1 reference

As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.

21 January 2018

1 reference

Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein

21 January 2018

1 reference